X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -807.5 27.7 - View Chart
P/BV x 0.2 5.3 4.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2181,044 20.9%   
Low Rs82818 10.0%   
Sales per share (Unadj.) Rs365.6298.6 122.5%  
Earnings per share (Unadj.) Rs1.557.2 2.6%  
Cash flow per share (Unadj.) Rs37.958.4 64.9%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs382.5249.5 153.3%  
Shares outstanding (eoy) m11.4422.72 50.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.1 13.2%   
Avg P/E ratio x101.016.3 620.7%  
P/CF ratio (eoy) x4.015.9 24.8%  
Price / Book Value ratio x0.43.7 10.5%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,71721,157 8.1%   
No. of employees `0001.00.5 207.3%   
Total wages/salary Rs m324400 81.1%   
Avg. sales/employee Rs Th4,100.713,787.4 29.7%   
Avg. wages/employee Rs Th318.0813.0 39.1%   
Avg. net profit/employee Rs Th16.72,643.3 0.6%   
INCOME DATA
Net Sales Rs m4,1836,783 61.7%  
Other income Rs m20353 5.7%   
Total revenues Rs m4,2037,136 58.9%   
Gross profit Rs m8121,617 50.2%  
Depreciation Rs m41727 1,566.9%   
Interest Rs m3806 6,905.5%   
Profit before tax Rs m351,938 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m18632 2.9%   
Profit after tax Rs m171,301 1.3%  
Gross profit margin %19.423.8 81.4%  
Effective tax rate %51.632.6 158.1%   
Net profit margin %0.419.2 2.1%  
BALANCE SHEET DATA
Current assets Rs m2,7716,984 39.7%   
Current liabilities Rs m1,9312,056 93.9%   
Net working cap to sales %20.172.6 27.6%  
Current ratio x1.43.4 42.2%  
Inventory Days Days12599 126.0%  
Debtors Days Days5424 224.5%  
Net fixed assets Rs m5,328244 2,181.1%   
Share capital Rs m114227 50.4%   
"Free" reserves Rs m4,1775,441 76.8%   
Net worth Rs m4,3765,668 77.2%   
Long term debt Rs m1,91125 7,642.0%   
Total assets Rs m8,4287,901 106.7%  
Interest coverage x1.1353.3 0.3%   
Debt to equity ratio x0.40 9,897.7%  
Sales to assets ratio x0.50.9 57.8%   
Return on assets %4.716.5 28.5%  
Return on equity %0.422.9 1.7%  
Return on capital %6.634.0 19.4%  
Exports to sales %00.2 0.0%   
Imports to sales %20.536.3 56.5%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m8582,465 34.8%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m8582,677 32.1%   
Net fx Rs m-858-2,662 32.2%   
CASH FLOW
From Operations Rs m469923 50.8%  
From Investments Rs m29317 9.2%  
From Financial Activity Rs m-464-481 96.4%  
Net Cashflow Rs m35759 4.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 22, 2017 01:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS